Broad Institute

JUNE 27, 2024

They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration. ZFPs are also common in human cells, meaning they are less likely to trigger an immune response against themselves than the bacterial Cas9.

Disease 142

Disease Therapies Clinical Trials Engineering 142

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Creative Biolabs

JULY 12, 2020

Professor Florian Klein, the paper’s corresponding author, explained, “our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19.” They are expected to enter clinical development later this year.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 14, 2020

Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

AUGUST 16, 2020

Dr James Hindley says T cells can create more antibodies if a person is exposed to the virus again. A company in Cardiff has developed a test for coronavirus T cells – which can potentially provide longer-term immunity to the virus than antibodies. Image caption. Image copyright. Getty Images/Juan Gaertner. Image caption.

Virus 52

Virus Vaccine Immune Response Government 52

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient. In the U.S.

Virus 52

Virus Vaccine Laboratories Science 52

PerkinElmer

JANUARY 25, 2023

Laboratory professionals in all areas of science have experienced significant changes in recent years, and 2022 was no exception. Experts in the diagnostics and life sciences industry look back on 2022 and lend their insights on the major trends and technologies shaping laboratories in 2023.

Science 52

Science Laboratories Immune Response Disease 52

Drug Target Review

SEPTEMBER 8, 2023

” Several years ago, Cheroutre and her colleagues released research findings demonstrating that retinoic acid (RA), derived from vitamin A, triggers the activation of nuclear RARα and fosters gene expression that is critical for the differentiation of regulatory T cells with suppressive abilities, ultimately dampening immune responses.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

APRIL 22, 2023

In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and combining them against the virus. Many antibodies used to treat covid infection during the pandemic have been so-called neutralizing antibodies that prevent the virus from infecting the cell. Source link: [link]

Virus 40

Virus Immune Response Laboratories Doctors 40

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 1.1.7), South Africa (B.1.351),

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

The Pharma Data

DECEMBER 23, 2020

scientists and public health experts, it was announced that there was a growing new strain of the SARS-CoV-2 virus that causes COVID-19. Researchers say, however, they have never seen a virus acquire more than a dozen mutations at once. A New Strain of SARS-CoV-2 ID’ed in UK. In a December 8, 2020 meeting with U.K.

Research 52

Research Virus Vaccine Hospitals 52

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

Codon

DECEMBER 12, 2024

It would also be undetectable by key parts of the human immune system. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine.

RNA 102

RNA DNA Vaccine Virus 102

The Pharma Data

APRIL 22, 2023

According to Kirimanjeswara, the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variants. These epitopes elicit an immune response from a broad selection of T cells, ensuring a sustained coverage of future variants.

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

The Pharma Data

FEBRUARY 23, 2022

The public health relevance of the refrigerator temperature-stable adjuvanted protein-based Sanofi-GSK vaccine is strongly supported by the induction of robust immune responses and a favorable safety profile in multiple settings. against any symptomatic COVID-19 disease in the seronegative population.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

DECEMBER 28, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. . HOUSTON , Dec. 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc.,

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., All patients entering the trial were hospitalized with laboratory-confirmed COVID-19 requiring low-flow oxygen, and all received other background standard-of-care as required. futility analysis).

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JANUARY 24, 2021

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Li, president, Merck Research Laboratories. “We

Vaccine 40

Vaccine Immune Response Virus Production 40

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

Codon

JULY 27, 2023

a lower risk of immune responses. A YouTuber, The Thought Emporium , is growing rat neurons in the laboratory. reports Cas9 proteins that can penetrate into the central nervous system without being packaged into an adeno-associated virus, all while causing a lower immune response than a prior version of the same technology.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

a lower risk of immune responses. A YouTuber, The Thought Emporium , is growing rat neurons in the laboratory. reports Cas9 proteins that can penetrate into the central nervous system without being packaged into an adeno-associated virus, all while causing a lower immune response than a prior version of the same technology.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

OCTOBER 20, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced results from an independent laboratory validating internal animal studies showing the ability of Annamycin to target lung localized tumors.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Treatment Virus 40

The Pharma Data

JANUARY 3, 2021

Preclinical data from our laboratory have shown that the nasal administration of anti-CD3 stimulates Tregs that can suppress inflammation and ameliorate inflammatory diseases. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

OCTOBER 22, 2020

The same virus has also been detected in sewage in Cairo, Egypt but with no evidence of local circulation. Routine immunization particularly outreach services was the area most frequently reported as disrupted. . Since the last meeting, exportation of WPV1 from Pakistan to Afghanistan has been documented. .

Vaccine 52

Vaccine International Immune Response Virus 52

The Pharma Data

JANUARY 29, 2021

In the study, the definition of severe COVID-19 disease included laboratory-confirmed SARS-CoV-2 and one or more of the following: signs consistent with severe systemic illness, admission to an intensive care unit, respiratory failure, shock, organ failure or death, among other factors. Global Head, Janssen Research & Development.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Clinical Trials 40

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos , M.D.,

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

MARCH 11, 2021

This clearly demonstrates the power of the COVID-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

NOVEMBER 1, 2020

The scientific concept, to activate nasal mucosal immunity by nasally administered Foralumab, is to fight against the virus in the respiratory tract and lungs,” stated Dr. Shailubhai, CEO and CSO of Tiziana Life Sciences. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses shown to cause lung damage in COVID-19.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

Codon

APRIL 9, 2023

Marine sponges were cultured in the laboratory continuously for the first time. Read Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. The RNA strands shut down a specific gene in the insects, and killed half after 7 days. The New England Journal of Medicine.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

OCTOBER 26, 2020

In addition, the observed median PFS shows that the regimen can induce a sustained and durable response, which is also shown consistently by the induction of a specific immune response. 27, 2020 06:30 UTC. Transgene has an ongoing Invir.IO collaboration with AstraZeneca. Follow us on Twitter: @TransgeneSA.

Vaccine 40

Vaccine Trials Treatment Virus 40

Agency IQ

DECEMBER 1, 2023

The guidance also provided insight on new issues that had arisen since the first version of the guidance was published ; for example, the potential for drug resistance and the impact of virus shedding and immune response. These topics were covered in the body of the guidance and were addressed in two new appendices.

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Pharma Data

JANUARY 21, 2021

Pfizer and BioNTech announced that their COVID-19 vaccine was probably just as effective against the variant strain of the virus, B.1.1.7, The Pfizer-BioNTech study indicated that they found “no biologically significant difference in neutralization activity” in laboratory tests from the original coronavirus strain and the B.1.1.7.

Research 52

Research DNA Vaccine Immune Response 52